BIOLYPH

Founded in 2004 and based in Morris Plains, New Jersey, BIOLYPH operates as a specialized Contract Development and Manufacturing Organization (CDMO) focused on lyophilization. Its core value proposition is enabling room-temperature stability for sensitive reagents and therapeutics, which can reduce logistics costs, simplify storage, and allow for novel product formulations. The company serves clients in drug delivery and diagnostics, offering a service-based model that leverages its proprietary formulation and process expertise. BIOLYPH appears to be a privately held, revenue-generating services firm catering to the growing demand for stable biologics and complex diagnostic assays.

Proprietary lyophilization (freeze-drying) process development and optimization platform for stabilizing biologics, small molecules, and diagnostic reagents at room temperature, enabling cold-chain elimination and co-formulation of incompatible components.

BIOLYPH competes with large, global CDMOs (e.g., Catalent, Lonza, Thermo Fisher) that offer lyophilization among many other services, as well as smaller niche lyophilization specialists. Differentiation hinges on deep technical expertise, customization, and a focus on complex formulation challenges.